BioArctic Logo

BioArctic

Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.

BIOA | ST

Overview

Corporate Details

ISIN(s):
SE0010323303 (+1 more)
LEI:
549300Y0OI2WVUNHLC33
Country:
Sweden
Address:
Warfvinges väg 35, 112 51 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 08:15
Regulatory News Service
Kina godkänner intravenös underhållsbehandling med Leqembi®
Swedish 235.6 KB
2025-09-29 08:15
Regulatory News Service
Leqembi® approved for IV maintenance treatment in China
English 229.9 KB
2025-09-24 08:40
Regulatory News Service
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
English 237.4 KB
2025-09-24 08:40
Regulatory News Service
Australien godkänner Leqembi® för behandling av tidig Alzheimers sjukdom
Swedish 225.9 KB
2025-09-03 17:35
Major Shareholding Notification
BioArctics grundare har för avsikt att sälja en mindre del av sitt aktieinnehav
Swedish 182.9 KB
2025-09-03 17:35
Major Shareholding Notification
BioArctic’s founders intend to divest minor part of their shareholding
English 179.0 KB
2025-09-03 01:30
Regulatory News Service
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as …
English 211.3 KB
2025-09-03 01:30
Regulatory News Service
Stegvis ansökningsprocess påbörjad för marknadsgodkännande i USA av Leqembi® Iq…
Swedish 253.3 KB
2025-09-01 18:30
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
English 196.1 KB
2025-09-01 18:30
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i BioArctic AB (publ) per den 29 augusti 2025
Swedish 209.2 KB
2025-08-29 23:56
Regulatory News Service
Amerikanska läkemedelsverket godkänner subkutan underhållsbehandling med Leqemb…
Swedish 251.3 KB
2025-08-29 23:55
Regulatory News Service
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for m…
English 212.0 KB
2025-08-28 08:00
Interim Report
Swedish 1.8 MB
2025-08-28 08:00
Interim Report
English 1.6 MB
2025-08-26 07:05
M&A Activity
BioArctic och Novartis ingår options-, samarbets- och licensavtal som nyttjar B…
Swedish 201.1 KB

Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioArctic via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-13 Gunilla Osswald Other Sell 40,000 8,821,200.00 SEK
2025-02-13 Gunilla Osswald Other Other 40,000 3,344,000.00 SEK
2025-02-13 Sten Mikael Moge Other Sell 6,000 1,323,180.00 SEK
2025-02-13 Sten Mikael Moge Other Other 6,000 501,600.00 SEK
2025-02-13 Johanna Margareta Fälting Other Sell 1,500 330,795.00 SEK
2025-02-13 Johanna Margareta Fälting Other Other 2,500 209,000.00 SEK
2025-02-13 Johanna Margareta Fälting Other Other 1,500 125,400.00 SEK
2025-01-10 Mikael Smedeby Other Buy 730 148,920.00 SEK
2024-12-19 Oskar Bosson Other Sell 2,000 446,000.00 SEK
2024-12-19 Oskar Bosson Other Sell 871 195,626.60 SEK

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.